Remote capillary blood collection for <scp>HbA_1c</scp> measurement during the <scp>COVID</scp>‐19 pandemic: A laboratory and patient perspective

Abstract

Abstract Aims The purpose of this study was to assess the clinical performance and user acceptance of capillary blood samples prepared remotely using the MiniCollect® capillary blood collection device as an alternative to blood collection by venepuncture for glycated haemoglobin (HbA 1c ) analysis. Methods Following written informed consent, a cross‐sectional study was conducted in individuals aged ≥18 years with any type of diabetes who routinely self‐monitor their blood glucose. Eligible participants recruited whilst attending their routine clinical appointments were required to provide a venous blood sample, prepare a capillary blood sample at home (remotely) and complete a bespoke questionnaire. HbA 1c in whole blood collected in ethylenediaminetetraacetic acid was determined by capillary electrophoresis on the Sebia Capillary's 3 Tera analyser following standard operating procedure. Results HbA 1c results from both venous and capillary collection demonstrated good agreement. Passing‐Bablok regression: y = 0 + 1 x ( p = 0.18), Spearman correlation r = 0.986, p &lt; 0.0001. The Bland–Altman difference plot provided a mean difference of 0.3 mmol/mol (2.2%). Over half of the participants found the MiniCollect device easy to use. The majority of participants were in favour of the remote capillary blood collection service and would use it if routinely available. Conclusion The home collection of capillary blood for HbA 1c determination is a valuable and convenient alternative to standard venous blood collection as it provides an opportunity to support routine HbA 1c monitoring, whilst mitigating the transmission of SARS‐CoV‐2. This service would additionally allow individuals to attend clinic visits with a HbA 1c value, ensuring optimal continuance of patient care for individuals with diabetes.

Topics & Concepts